Standard ways of reimbursing for innovations can create disincentives for the development of high-value innovations in health care. One remedy is the development of “Netflix-like” subscription models that entail paying a subscription fee for access to drugs and treatments. Such models are already in use in the United Kingdom, Australia, and Sweden.